An anti-anterior gradient 3 mouse monoclonal antibody
| Institute |
|---|
| Moravian Biotechnology |
| SKU: | 162065 |
|---|---|
| Product description: | Antibody created to detect the human AGR3 and AGR2 proteins. Binding specificity: Human AGR3 and AGR2 proteins. Epitope PLMII (determined using pepscan). |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Molecular weight: | AGR3: Calculated: 19,6 kDa; SDS-PAGE mobility (reduced): 19-20 kDa; AGR2: Calculated: 19,9 kDa; SDS-PAGE mobility (reduced): 19-20 kDa |
| Immunogen: | Purified human AGR3 protein |
| Cat. #: | 162065 |
|---|---|
| Tool sub type: | Primary antibody |
| Target: | Human Anterior gradient 3 and human Anterior gradient 2 |
| Reactivity: | Human |
| Clone: | AGR3.3 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | AGR3 (Anterior Gradient 3) is a human homologue of the XAG-3 protein expressed in Xenopus laevis, which were identified in a study analyzing mRNA expression in ER-positive breast cancer-derived cell lines. The two proteins show a considerable degree of similarity, with the coding sequences of both proteins located in close proximity on the chromosome at position 7p21. AGR3 expression in ovarian cancer is independent of oestrogen-receptor expression, which is distinct from the oestrogen-receptor dependent expression of AGR3 in breast cancers. Isogenic cancer cell models were created that over-express AGR3 and these demonstrated that AGR3 mediates cisplatin-resistance in mouse xenografts. These data indicate that AGR3 is over-expressed by a hormone (oestrogen-receptor ?)-independent mechanism and identify a novel protein-folding associated pathway that could mediate resistance to DNA-damaging agents in human cancers. AGR2 has been characterized in more detail so far and has been shown to be directly involved in the neoplastic transformation of the cell as well as in their migration. Thus, the results obtained so far support the hypothesis that AGR2 plays an important role in mediating some pro-oncogenic signals of estrogen receptors. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.